Alexandria Real Estate Equities, Inc

Alexandria Real Estate Equities, Inc(ARE)股票分析

$42.340

+0.855 (+2.02%)收盘时

Loading chart…
最高
42.980
开盘
42.250
成交量加权均价
42.39
成交量
2.38M
市值
20.35B
最低
41.860
成交额
100.86M
企业价值/息税折旧摊销前利润(TTM)
11.40

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.

AI 分析 of Alexandria Real Estate Equities, Inc (ARE)

卖出

Alexandria Real Estate Equities Inc is not a good buy right now due to significant financial instability and negative market sentiment. The current price is $45.51, with an RSI of 23.288 indicating the stock is oversold. Additionally, the stock has experienced a 38.39% decline over the past year, contrasting sharply with the S&P 500's 17.2% gain, suggesting a lack of investor confidence. The main risk is the company's high debt-to-equity ratio of 66.85%, which raises concerns about its financial health and ability to recover.

分析师评级(12)

上行空间 +34.27%
买入
7 买入
5 持有
0 卖出
当前: 42.34
最低
41.00
平均
56.85
最高
67.00

BMO Capital

2026-10-12

目标价

$41

Market Perform

JPMorgan

2026-09-24

目标价

$56

减持

Evercore ISI

2026-09-21

目标价

$59

跑赢大盘

Baird

2026-08-24

目标价

$52

中性

BofA

2026-08-24

目标价

$55

中性

估值指标

Alexandria Real Estate Equities, Inc(ARE)当前预期市盈率为 16.69,5 年平均预期市盈率为 47.14。

预期市盈率

合理
5 年均值 P/E
47.14
当前P/E
16.69
高估
82.83
低估
11.45

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
20.36
当前EV/EBITDA
11.40
高估
28.36
低估
12.35

预期市销率

低估
5 年均值 P/S
6.72
当前P/S
2.83
高估
9.57
低估
3.88

Alphio AI 对 ARE 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%ARE

$70.33

情景价格

基

基准

基准 · 50%ARE

$69.46

情景价格

悲

悲观

悲观 · 25%ARE

$59.44

情景价格

持有 ARE 的大户

S

Stichting Pensioenfonds ABP

+ 持有ARE

+3.14%

3个月收益率

C

Clal Financial Management Ltd

+ 持有ARE

-0.93%

3个月收益率

Q

Quinn Opportunity Partners LLC

+ 持有ARE

-4.28%

3个月收益率

C

CenterSquare Investment Management LLC

+ 持有ARE

-9.13%

3个月收益率

ARE 常见问题 —— 由 Alphio AI 解答

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry. It operates in the Real Estate sector (REAL ESTATE INVESTMENT TRUSTS industry).

Alexandria Real Estate Equities Inc is not a good buy right now due to significant financial instability and negative market sentiment. The current price is $45.51, with an RSI of 23.288 indicating the stock is oversold. Additionally, the stock has experienced a 38.39% decline over the past year, contrasting sharply with the S&P 500's 17.2% gain, suggesting a lack of investor confidence. The main risk is the company's high debt-to-equity ratio of 66.85%, which raises concerns about its financial health and ability to recover.

12 analysts cover ARE: 7 rate it Buy, 5 Hold and 0 Sell. The average price target is 56.85.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易